| About the author: |
N. I. Voloshchuk, V. G. Zolotareva, A. V. Hara, O. S. Pashynska, I. V. Taran, A. V. Melnyk, V. O. Denysiuk |
| Heading |
EXPERIMENTAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The global prevalence of metabolic syndrome in Ukraine and the world gives reason to consider it one of the most dangerous diseases of the modern world. One of the promising directions in the pharmacotherapy of pathological conditions is the use of the drug in the form of bioidentical implants that contain a medicinal substance. Experimental metabolic syndrome in animals was modeled with the help of a Cafeteria diet, which imitated the problematic eating patterns of modern humans. Animal body weight, blood glucose, lactate and insulin content, HOMA index, and lipid metabolism indicators were evaluated as markers of metabolic syndrome and criterion signs of treatment effectiveness. Results showed that a 6-week Cafeteria diet causes a metabolic imbalance and is accompanied by signs characteristic of metabolic syndrome. Probable signs of insulin resistance accompanied these changes. Both the tablet and pellet form of the drug positively affected the indicators of carbohydrate metabolism and reduced the manifestations of insulin resistance. Metformin in bioidentical implants also significantly improved experimental animals' general condition and appearance. |
| Tags |
metabolic syndrome,metformin,laboratory animals,lipid spectrum,hyperglycemia,insulin resistance,pellets |
| Bibliography |
- Kachula SO. Biokhimichnyi status ta stan perekysnoho okysnennia lipidiv v shchuriv za umov holoduvannia. Visnyk Vinnytskoho natsionalnoho medychnoho universytetu. 2013; 1(17):15-16. [in Ukrainian].
- Urbanovych AM. Metformin: novi hrani ta mozhlyvosti. Zdorovya Ukrainy. 2021; 4(56): elektronnyi resurs. Kod dostupu https://health-ua.com/multimedia/6/8/8/4/7/1643099980.pdf [in Ukrainian].
- Cho Y, Lee SY. Useful Biomarkers of Metabolic Syndrome. International Journal of Environmental Research and Public Health. 2022; 19(22):15003. doi: 10.3390/ijerph192215003.
- Fadden EJ, Longley C, Mahambrey T. Metformin-associated lactic acidosis. BMJ Case Reports. 2021; 14(7): e239154. doi: 10.1136/bcr-2020-239154.
- Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: Updates on pathophysiology and management in 2021. International Journal of Molecular Sciences. 2022; 23(2):786. doi: 10.3390/ijms23020786.
- Kim K. Rethinking about metformin: Promising potentials. Korean Journal of Family Medicine. 2024; Aug 23. doi: 10.4082/kjfm.24.0156.
- Lalanza JF, Snoeren EMS. The cafeteria diet: A standardized protocol and its effects on behavior. Neuroscience & Biobehavioral Reviews. 2021; 122:92-119. doi: 10.1016/j.neubiorev.2020.11.003.
- McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016; 59(3):426-435. doi: 10.1007/s00125-015-3844-9.
- Mian A, Bani Fawwaz BA, Singh G, Farooq A, Koteish A. Metformin-induced acute hepatitis. Cureus. 2023; 15(5): e38908. doi: 10.7759/cureus.38908.
- Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, Sabater M, Pardo G, Ricart W, et al. OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes. 2011; 60(1):168-176. doi: 10.2337/db10-0805.
- Podhorecka M, Ibanez B, Dmoszyńska A. Metformin – its potential anti-cancer and anti-aging effects. Postępy Higieny i Medycyny Doswiadczalnej (Online). 2017; 71(0):170-175. doi: 10.5604/01.3001.0010.3801.
- Saklayen MG. The global epidemic of the metabolic syndrome. Current Hypertension Reports. 2018; 20(2):12. doi: 10.1007/s11906-018-0812-z.
- Tamblyn J, Robinson L, Maguire E, Hodge A, Briggs P. Subcutaneous hormone implants. Post Reproductive Health. 2023; 29(4):240-243. doi: 10.1177/20533691231214870.
- Xie Z, Hu J, Gu H, Li M, Chen J. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. Frontiers in Endocrinology (Lausanne). 2023; 14:1244432. doi: 10.3389/fendo.2023.1244432.
- Zhou Z, Hultgren KE. Complementing the US Food and Drug Administration adverse event reporting system with adverse drug reaction reporting from social media: Comparative analysis. JMIR Public Health Surveillance. 2020; 6(3): e19266. doi: 10.2196/19266.
|
| Publication of the article |
«World of Medicine and Biology» №3(89), 2024 year, 220-224 pages, index UDK 616-03:616-008.9:569.323 |
| DOI |
10.26724/2079-8334-2024-3-89-220-224 |
